keyword
MENU ▼
Read by QxMD icon Read
search

vonoprazan

keyword
https://www.readbyqxmd.com/read/28664410/efficacy-of-vonoprazan-based-triple-therapy-for-helicobacter-pylori-eradication-a-multicenter-study-and-a-review-of-the-literature
#1
Hiroki Tanabe, Katsuyoshi Ando, Kiichi Sato, Takahiro Ito, Mitsuru Goto, Tomonobu Sato, Akihiro Fujinaga, Toru Kawamoto, Tatsuya Utsumi, Nobuyuki Yanagawa, Eiichiro Ichiishi, Takaaki Otake, Yutaka Kohgo, Yoshiki Nomura, Nobuhiro Ueno, Hiroko Sugano, Shin Kashima, Kentaro Moriichi, Mikihiro Fujiya, Toshikatsu Okumura
BACKGROUND: Eradication therapies for Helicobacter pylori infection are advancing as new acid inhibitory reagents approved. The aim of this study was to assess the efficacy and safety of vonoprazan-based triple treatment. MATERIALS AND METHODS: Triple therapy with vonoprazan and two antibiotics (amoxicillin and clarithromycin or metronidazole) received focus in this analysis. We performed a multicenter retrospective study of patients who received vonoprazan-based eradication therapy between February 2015 and February 2016 and conducted a review of the literature...
June 29, 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/28662503/the-effects-of-switching-to-vonoprazan-a-novel-potassium-competitive-acid-blocker-on-gastric-acidity-and-reflux-patterns-in-patients-with-erosive-esophagitis-refractory-to-proton-pump-inhibitors
#2
Hiroshi Yamashita, Atsushi Kanamori, Chise Kano, Hiroki Hashimura, Kei Matsumoto, Masahiro Tsujimae, Tetsuya Yoshizaki, Kenji Momose, Daisuke Obata, Takaaki Eguchi, Mikio Fujita, Akihiko Okada
BACKGROUND/AIM: The effects of vonoprazan and proton pump inhibitors (PPIs) in patients with reflux esophagitis (RE) have not yet been compared using multichannel intraluminal impedance-pH (MII-pH). METHODS: A total of 8 patients with persistent gastric mucosal injury, despite completing an 8-week standard PPI therapy, were enrolled in the study. While they were on standard PPI therapy, the baseline values of reflux parameters, holding time ratio (HTR) of gastric pH >4, and esophageal pH <4 were obtained by using 24 h MII-pH monitoring...
June 30, 2017: Digestion
https://www.readbyqxmd.com/read/28657473/vonoprazan-fumarate-for-the-management-of-acid-related-diseases
#3
Irene Martinucci, Corrado Blandizzi, Giorgia Bodini, Elisa Marabotto, Vincenzo Savarino, Santino Marchi, Nicola de Bortoli, Edoardo Savarino
Proton pump inhibitors (PPIs) display a number of limitations and unmet clinical needs that have prompted the development of novel drugs to improve the outcomes of acid-related diseases, including the eradication of H. pylori. In this context, a new synthesized potassium-competitive acid blocker (P-CAB), vonoprazan, showed higher suppression of gastric acid secretion. Areas covered: This review discusses the current knowledge regarding the efficacy of vonoprazan in the treatment of acid-related diseases, with a particular focus on its use in Helicobacter pylori eradication...
August 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28584402/effects-of-patient-age-and-choice-of-antisecretory-agent-on-success-of-eradication-therapy-for-helicobacter-pylori-infection
#4
Toshihiro Nishizawa, Hidekazu Suzuki, Ai Fujimoto, Hiroto Kinoshita, Shuntaro Yoshida, Yoshihiro Isomura, Akira Toyoshima, Takanori Kanai, Naohisa Yahagi, Osamu Toyoshima
The effects of patient age on the efficacy of eradication treatment for Helicobacter pylori (H. pylori) remain unclear. The present study aimed to determine whether age affects eradication therapy involving vonoprazan, a novel potassium-competitive acid blocker (PCAB). We reviewed the cases of 3,261 patients who were administered first-line and second-line H. pylori eradication therapy at Toyoshima Endoscopy Clinic. The first-line treatment was clarithromycin and amoxicillin combined with a proton pump inhibitor (PPI) or a PCAB...
May 2017: Journal of Clinical Biochemistry and Nutrition
https://www.readbyqxmd.com/read/28578848/study-on-pharmacokinetics-and-bioequivalence-of-vonoprazan-pyroglutamate-in-rats-by-liquid-chromatography-with-tandem-mass-spectrometry
#5
Yuan Qiao, Jun Zhao, Xuanfeng Yue, Yang Zhang, Ruitao Zhang, Yuan Xu, Xiuling Tang, Xueying Liu, Qingwei Wang
Vonoprazan Fumarate (TAK-438F) is a new and effective drug approved in Japan in 2014 for treatment and prevention of acid-related diseases (ARDs), which exhibits many advantages compared with traditional proton-pump inhibitors (PPIs). However, the clinical applications of TAK0-438F suffers limitation due to the lack of injection dosage form. Efforts to overcome this limitation lead to the systhesis of Vonoprazan pyroglutamate (TAK-438P) for its high water solubility and more potent antisecretory effect. This was the first report to establish and validate a reliable and sensitive LC-MS/MS method for the quantification of TAK-438P in rat plasma and tissues (heart, liver, spleen, liver, kidney, rain, stomach and small intestine)...
August 1, 2017: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
https://www.readbyqxmd.com/read/28567114/a-randomized-double-blind-study-to-evaluate-the-acid-inhibitory-effect-of-vonoprazan-20-mg-and-40-mg-in-patients-with-proton-pump-inhibitor-resistant-erosive-esophagitis
#6
Katsuhiko Iwakiri, Yuuichi Sakurai, Madoka Shiino, Hiroyuki Okamoto, Kentaro Kudou, Akira Nishimura, Naoki Hiramatsu, Eiji Umegaki, Kiyoshi Ashida
BACKGROUND: Standard treatment for patients with erosive esophagitis (EE) is proton-pump inhibitors (PPIs), but some patients are resistant to PPIs. We aimed to evaluate the acid-inhibitory effects and efficacy of a novel potassium-competitive acid blocker (vonoprazan) in patients with PPI-resistant EE. METHODS: This randomized, double-blind, multicenter study of vonoprazan evaluated gastric and esophageal pH over a 24-hour period as the primary endpoint and EE healing rate as the secondary endpoint...
June 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/28566587/the-superiority-of-vonoprazan-based-first-line-triple-therapy-with-clarithromycin-a-prospective-multi-center-cohort-study-on-helicobacter-pylori-eradication
#7
Soichiro Sue, Hirofumi Kuwashima, Yuri Iwata, Hiroyuki Oka, Isao Arima, Takehide Fukuchi, Katsuyuki Sanga, Yasuhiro Inokuchi, Yuniba Ishii, Masatomo Kanno, Masahiro Terada, Hitoshi Amano, Makoto Naito, Shigeru Iwase, Hiroshi Okazaki, Kazuto Komatsu, Atsushi Kokawa, Ichiro Kawana, Manabu Morimoto, Toshifumi Saito, Yosuke Kunishi, Akihiko Ikeda, Daisuke Takahashi, Haruo Miwa, Tomohiko Sasaki, Toshihide Tamura, Masaaki Kondo, Wataru Shibata, Shin Maeda
Objective We evaluated the safety and efficacy of vonoprazan-based amoxicillin and clarithromycin 7-day triple therapy (VAC) in comparison to proton pump inhibitor (PPI)-based (PAC) as a first-line treatment and vonoprazan-based amoxicillin and metronidazole 7-day triple therapy (VAM) in comparison to PPI-based (PAM) as a second-line treatment for the eradication of Helicobacter pylori in Japan. Methods We performed a non-randomized, multi-center, parallel-group study to compare first-line VAC to PAC and second-line VAM to PAM...
2017: Internal Medicine
https://www.readbyqxmd.com/read/28529929/novel-and-effective-therapeutic-regimens-for-helicobacter-pylori-in-an-era-of-increasing-antibiotic-resistance
#8
REVIEW
Yi Hu, Yin Zhu, Nong-Hua Lu
Helicobacter pylori (H. pylori) is a common gastrointestinal bacterial strain closely associated with the incidence of chronic gastritis, peptic ulcers, gastric mucosa-associated lymphoid tissue lymphoma, and gastric cancer. A current research and clinical challenge is the increased rate of antibiotic resistance in H. pylori, which has led to a decreased H. pylori eradication rate. In this article, we review recent H. pylori infection and reinfection rates and H. pylori resistance to antibiotics, and we discuss the pertinent treatments...
2017: Frontiers in Cellular and Infection Microbiology
https://www.readbyqxmd.com/read/28501868/factors-associated-with-potassium-competitive-acid-blocker-non-response-in-patients-with-proton-pump-inhibitor-refractory-gastroesophageal-reflux-disease
#9
Masatsugu Okuyama, Kenichi Nakahara, Narika Iwakura, Tomoki Hasegawa, Maizumi Oyama, Ayumi Inoue, Hirotaka Ishizu, Hiroshi Satoh, Yasuhiro Fujiwara
BACKGROUND/AIMS: Approximately 20-40% of patients with gastroesophageal reflux disease (GERD) are refractory to proton pump inhibitor (PPI) treatment. The acid-inhibitory effect of vonoprazan, a novel potassium-competitive acid blocker (P-CAB), is significantly greater when compared to the effect of PPIs. We investigated the efficacy of vonoprazan treatment for PPI-refractory GERD and factors associated with P-CAB non-response. METHODS: We enrolled 277 GERD patients receiving continuous PPI therapy...
2017: Digestion
https://www.readbyqxmd.com/read/28497487/systematic-review-with-meta-analysis-the-efficacy-of-vonoprazan-based-triple-therapy-on-helicobacter-pylori-eradication
#10
REVIEW
Y S Jung, E H Kim, C H Park
BACKGROUND: In order to increase eradication rates, vonoprazan, a novel potassium-competitive acid blocker, has been used in Helicobacter pylori eradication therapy. AIM: To summarise the results of the efficacy of vonoprazan-based triple therapy, helping clinicians to better understand the benefit of vonoprazan in the treatment of H. pylori infection. METHODS: We conducted a systematic literature search on MEDLINE, EMBASE, and the Cochrane Library using the primary keywords "vonoprazan," "takecab", "TAK-438," "potassium," "competitive," "potassium-competitive," "Helicobacter," and "pylori...
July 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28357069/efficacy-of-a-potassium-competitive-acid-blocker-for-improving-symptoms-in-patients-with-reflux-esophagitis-non-erosive-reflux-disease-and-functional-dyspepsia
#11
Daisuke Asaoka, Akihito Nagahara, Mariko Hojo, Kenshi Matsumoto, Hiroya Ueyama, Kohei Matsumoto, Kentaro Izumi, Tsutomu Takeda, Hiroyuki Komori, Yoichi Akazawa, Yuji Shimada, Taro Osada, Sumio Watanabe
The aim of the present study was to investigate the efficacy of a potassium-competitive acid blocker (PCAB) named vonoprazan (VPZ) for improving symptoms in patients with reflux esophagitis (RE), non-erosive reflux disease (NERD), and functional dyspepsia (FD). A hospital-based, retrospective study of outpatients in our department (Department of Gastroenterology, University of Juntendo, Tokyo, Japan) between March 2015 and August 2016 was performed. The patients who were experiencing heartburn, acid regurgitation, gastric pain, and/or a heavy feeling in the stomach of at least moderate severity at baseline were treated with 20 mg VPZ once daily for 4 weeks...
February 2017: Biomedical Reports
https://www.readbyqxmd.com/read/28349044/vonoprazan-based-regimen-is-more-useful-than-ppi-based-one-as-a-first-line-helicobacter-pylori-eradication-a-randomized-controlled-trial
#12
Masafumi Maruyama, Naoki Tanaka, Daisuke Kubota, Masayuki Miyajima, Takefumi Kimura, Koujiro Tokutake, Ryujiro Imai, Toru Fujisawa, Hiromitsu Mori, Yoshiaki Matsuda, Shuichi Wada, Akira Horiuchi, Kendo Kiyosawa
Background. A new agent, potassium-competitive acid blocker vonoprazan (VPZ) has potent acid-inhibitory effects and may offer advantages over conventional H. pylori eradication therapies. We aimed to compare the eradication rate between VPZ-based treatment and PPI-based one. Methods. This randomized controlled trial was designed to assign 141 patients with H. pylori-positive gastritis to VPZ group (VPZ 20 mg, amoxicillin 750 mg, and clarithromycin 200 or 400 mg twice daily for 7 days) or PPI group (rabeprazole 20 mg or lansoprazole 30 mg, amoxicillin 750 mg, and clarithromycin 200 or 400 mg twice daily for 7 days)...
2017: Canadian Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28267236/effect-of-vonoprazan-on-the-treatment-of-artificial-gastric-ulcers-after-endoscopic-submucosal-dissection-prospective-randomized-controlled-trial
#13
Izumi Tsuchiya, Yuri Kato, Emiko Tanida, Yoshifumi Masui, Shingo Kato, Atsushi Nakajima, Motoyoshi Izumi
BACKGROUND AND AIM: Proton pump inhibitors are effective for the treatment of gastric ulcers after endoscopic submucosal dissection (ESD). However, the most excellent therapy is controversial. Vonoprazan, an active potassium-competitive acid blocker, has a strong gastric acid secretion inhibitory effect, but its efficacy for the treatment of post-ESD gastric ulcers is unclear. Herein, we aimed to determine the healing effect of vonoprazan on post-ESD gastric ulcers. METHODS: We carried out a prospective randomized controlled trial examining 92 patients who had undergone ESD for the treatment of gastric neoplasms between April 2015 and June 2016 at Machida Municipal Hospital...
March 7, 2017: Digestive Endoscopy: Official Journal of the Japan Gastroenterological Endoscopy Society
https://www.readbyqxmd.com/read/28216974/comparative-study-vonoprazan-and-proton-pump-inhibitors-in-helicobacter-pylori-eradication-therapy
#14
Kouichi Sakurai, Hiroko Suda, Yumi Ido, Takayuki Takeichi, Ayako Okuda, Kiwamu Hasuda, Masahiro Hattori
AIM: To compare the effectiveness and safety of vonoprazan-based therapy with proton pump inhibitor (PPI)-based therapies to treat Helicobacter pylori (H. pylori). METHODS: We retrospectively analysed data from first-line (vonoprazan or PPI with 200 mg clarithromycin and 750 mg amoxicillin twice daily for 7 d) (n = 1353) and second-line (vonoprazan or PPI with 250 mg metronidazole and 750 mg amoxicillin twice daily for 7 d) (n = 261) eradication treatments for H...
January 28, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28198590/effect-of-therapeutic-and-supratherapeutic-doses-of-vonoprazan-on-the-qt-qtc-interval-in-a-phase-i-randomized-study-in-healthy-subjects
#15
B Astruc, H Jenkins, R Jenkins
This phase I, randomized, 4-period, 4-sequence, double-blind, active- and placebo-controlled, crossover study assessed the effects of vonoprazan on the QT/QTc interval in healthy subjects. Subjects received single oral doses of vonoprazan 40 mg, vonoprazan 120 mg, moxifloxacin 400 mg (positive control/open label), and placebo. The primary end point was time-matched, placebo-corrected, baseline-adjusted mean Fridericia-corrected QT interval (ddQTcF). Of 64 subjects (mean age, 37.8 years; 50% male), 63 received all four regimens...
May 2017: Clinical and Translational Science
https://www.readbyqxmd.com/read/28098408/vonoprazan-improves-the-efficacy-of-helicobacter-pylori-eradication-therapy-with-a-regimen-consisting-of-clarithromycin-and-metronidazole-in-patients-allergic-to-penicillin
#16
Shoko Ono, Mototsugu Kato, Soichi Nakagawa, Katsuhiro Mabe, Naoya Sakamoto
BACKGROUND: Although all Helicobacter pylori (H. pylori)-positive patients should receive eradication therapy, the therapy is a challenge for patients allergic to penicillin. There have been a few reports on the efficacy of eradication therapy for such patients. OBJECTIVE: To analyze the efficacy of vonoprazan or proton pump inhibitor (PPI)-based 7-day triple therapy in patients allergic to penicillin. MATERIALS AND METHODS: A total of 88 consecutive patients allergic to penicillin who received H...
January 18, 2017: Helicobacter
https://www.readbyqxmd.com/read/28030862/a-comparative-study-of-a-new-class-of-gastric-acid-suppressant-agent-named-vonoparazan-versus-esomeprazole-for-the-eradication-of-helicobacter-pylori
#17
COMPARATIVE STUDY
Masahiro Tsujimae, Hiroshi Yamashita, Hiroki Hashimura, Chise Kano, Keiko Shimoyama, Atsushi Kanamori, Kei Matsumoto, Akio Koizumi, Kenji Momose, Takaaki Eguchi, Takumi Fukuchi, Mikio Fujita, Akihiko Okada
BACKGROUND: Helicobacter pylori eradication rates have decreased worldwide. Gastric acid inhibition during treatment is important to eradicate these bacteria successfully. A new potassium-competitive acid blocker, vonoprazan (VPZ), has been shown to achieve high eradication rates in a previous randomized controlled trial. OBJECTIVE: To determine the efficacy of VPZ for H. pylori eradication. METHODS: A total of 874 patients were enrolled; 431 received esomeprazole (EPZ) and 443 received VPZ...
2016: Digestion
https://www.readbyqxmd.com/read/27988924/successful-eradication-therapy-for-helicobacter-pylori-positive-atrophic-gastritis-at-the-sixth-attempt-a-case-report
#18
Ryuzo Deguchi, Koichi Shiraishi, Yoshitaka Arase, Makiko Dekiden, Hideo Shimada, Hiroshi Miyakita, Takashi Ogimi, Kazunori Myojin, Tetsuya Mine
A 74-year-old woman undergoing outpatient follow-up for reflux esophagitis and atrophic gastritis tested positive for Helicobacter pylori and underwent primary eradication therapy with lansoprazole (LPZ) 30 mg, amoxicillin (AMPC) 750 mg, and clarithromycin (CAM) 200 mg twice daily for 1 week in August 2012. A urea breath test (UBT) after this treatment revealed that eradication had failed. Secondary eradication therapy was carried out with esomeprazole (EPZ) 20 mg, AMPC 750 mg, and metronidazole (MNZ) 250 mg twice daily for 1 week, but this also failed...
December 20, 2016: Tokai Journal of Experimental and Clinical Medicine
https://www.readbyqxmd.com/read/27928738/effect-of-multiple-oral-doses-of-the-potent-cyp3a4-inhibitor-clarithromycin-on-the-pharmacokinetics-of-a-single-oral-dose-of-vonoprazan-a-phase-i-open-label-sequential-design-study
#19
Helen Jenkins, Richard Jenkins, Alain Patat
BACKGROUND AND OBJECTIVES: This phase I, open-label, sequential design study assessed the effect of multiple oral doses of the potent cytochrome P450 (CYP) 3A4 inhibitor clarithromycin on the pharmacokinetics of a single oral dose of vonoprazan. METHODS: During the 10-day treatment period, 16 healthy male subjects received vonoprazan 40 mg on days 1 and 8, and clarithromycin 1000 mg on days 3-9, with the pharmacokinetics of both examined. Primary endpoints included the maximum observed plasma concentration (C max) and area under the plasma concentration-time curve (AUC) of vonoprazan and its major metabolites (M-I, M-II, M-III, and M-IV-Sul)...
March 2017: Clinical Drug Investigation
https://www.readbyqxmd.com/read/27909552/vonoprazan-20-mg-vs-lansoprazole-30-mg-for-endoscopic-submucosal-dissection-induced-gastric-ulcers
#20
Kazuya Takahashi, Yuichi Sato, Junji Kohisa, Jun Watanabe, Hiroki Sato, Kenichi Mizuno, Satoru Hashimoto, Shuji Terai
AIM: To compare the healing effects of vonoprazan and lansoprazole on gastric ulcers induced by endoscopic submucosal dissection (ESD). METHODS: Data were obtained from a total of 26 patients. Fourteen patients were randomized to the vonoprazan group and 12 were randomized to the lansoprazole group. Patients were administered either 20 mg vonoprazan or 30 mg lansoprazole per day after ESD. Endoscopic images just after ESD, on day 8, and on day 28 were used for the evaluation of the shrinking rate of ESD ulcers...
November 16, 2016: World Journal of Gastrointestinal Endoscopy
keyword
keyword
99659
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"